Improvement of Certolizumab Fab′ properties by PASylation technology

Certolizumab pegol is a Fab′ antibody fragment for treatment of rheumatoid arthritis and Crohn’s disease which is conjugated to a 40 kDa PEG molecule in order to increase the protein half-life. PEGylation may have disadvantages including immunogenicity, hypersensitivity, vacuolation, decreased bindi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazaheri, Somayeh, Talebkhan, Yeganeh, Mahboudi, Fereidoun, Nematollahi, Leila, Cohan, Reza Ahangari, Mirabzadeh Ardakani, Esmat, Bayat, Elham, Sabzalinejad, Masoumeh, Sardari, Soroush, Torkashvand, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595094/
https://www.ncbi.nlm.nih.gov/pubmed/33116155
http://dx.doi.org/10.1038/s41598-020-74549-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595094/
https://www.ncbi.nlm.nih.gov/pubmed/33116155
http://dx.doi.org/10.1038/s41598-020-74549-0

Ejemplares similares